Adaptive Biotechnologies Corporation
NasdaqGS:ADPT 株式レポート
Adaptive Biotechnologies 将来の成長
Adaptive Biotechnologies利益と収益がそれぞれ年間24.9%と17.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-93% 26.1%なると予測されています。
主要情報
| Life Sciences 収益成長 | 18.8% |
| 収益成長率 | 17.5% |
| 将来の株主資本利益率 | -93.0% |
| アナリストカバレッジ | Good |
| 最終更新日 | 11 Nov 2024 |
今後の成長に関する最新情報
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09業績と収益の成長予測
NasdaqGS:ADPT - アナリストの将来予測と過去の財務データ ( )USD Millions| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|
| 12/31/2026 | 259 | -103 | -29 | -96 | 6 |
| 12/31/2025 | 209 | -141 | -57 | -127 | 8 |
| 12/31/2024 | 177 | -165 | -73 | -122 | 6 |
| 9/30/2024 | 177 | -195 | -115 | -110 | N/A |
| 6/30/2024 | 169 | -213 | -137 | -129 | N/A |
| 3/31/2024 | 175 | -215 | -145 | -136 | N/A |
| 12/31/2023 | 170 | -225 | -167 | -156 | N/A |
| 9/30/2023 | 180 | -196 | -171 | -159 | N/A |
| 6/30/2023 | 190 | -191 | -170 | -155 | N/A |
| 3/31/2023 | 184 | -195 | -195 | -179 | N/A |
| 12/31/2022 | 185 | -200 | -200 | -184 | N/A |
| 9/30/2022 | 168 | -221 | -231 | -208 | N/A |
| 6/30/2022 | 160 | -232 | -241 | -209 | N/A |
| 3/31/2022 | 155 | -229 | -248 | -199 | N/A |
| 12/31/2021 | 154 | -207 | -254 | -193 | N/A |
| 9/30/2021 | 147 | -190 | -241 | -179 | N/A |
| 6/30/2021 | 133 | -171 | -234 | -182 | N/A |
| 3/31/2021 | 116 | -155 | -208 | -176 | N/A |
| 12/31/2020 | 98 | -146 | -168 | -150 | N/A |
| 9/30/2020 | 92 | -122 | -148 | -137 | N/A |
| 6/30/2020 | 92 | -99 | -131 | -120 | N/A |
| 3/31/2020 | 93 | -82 | -115 | -105 | N/A |
| 12/31/2019 | 85 | -70 | 194 | 205 | N/A |
| 9/30/2019 | 78 | -62 | 215 | 227 | N/A |
| 6/30/2019 | 69 | -56 | 235 | 245 | N/A |
| 3/31/2019 | 59 | -53 | 243 | 252 | N/A |
| 12/31/2018 | 56 | -46 | -39 | -32 | N/A |
| 12/31/2017 | 38 | -43 | N/A | -35 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: ADPT今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: ADPT今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: ADPT今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: ADPTの収益 ( 17.5% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。
高い収益成長: ADPTの収益 ( 17.5% ) 20%よりも低い成長が予測されています。
将来の株主資本利益率
将来のROE: ADPT 3 年以内に赤字になると予測されています。
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
